Key Highlights

  • AOTI rose 32.58% to 87.5p after US Medicare contractors proposed nationwide coverage criteria for topical oxygen therapy in selected diabetic foot ulcers.
  • The proposal could materially widen access to AOTI's TWO2 therapy, but it remains subject to consultation, finalisation and effective reimbursement implementation.
  • FY2025 revenue grew 14% to $66.5 million, while receivables and net debt increased and Arizona Medicaid payment delays remained a significant constraint.

AOTI, Inc. (LSE: AOTI) rose 32.58% to 87.5p after US Medicare administrative contractors issued a proposed nationwide Local Coverage Determination for topical oxygen therapy in eligible diabetic foot ulcers. The development is directly relevant to AOTI's TWO2 system and could widen reimbursement. It is still a proposal: final wording, timing, payment rules and the company's ability to serve and collect from a larger patient base will determine the commercial result.

Company Overview

AOTI is a wound-care technology company headquartered in the United States with operations in Ireland. Its main platform, TWO2, delivers cyclical, pressurised topical oxygen to chronic wounds in the home or outpatient setting. The company also markets the NEXA negative-pressure wound therapy platform.

The business earns revenue by supplying therapies and related services through payer channels that include Medicaid, commercial insurers, veterans' healthcare and private reimbursement. That model makes clinical evidence important, but payer policy and claims collection are equally central. A therapy may be effective and still scale slowly if coverage is narrow or payment is delayed.

Why The Shares Are Attracting Attention

The proposed LCD would cover topical oxygen for qualifying Medicare beneficiaries whose diabetic foot ulcers have not healed after four consecutive weeks of optimised care. AOTI highlights Medicare's roughly 69 million enrollees and estimates a current US serviceable market of about $400 million, with a far larger long-term opportunity. Those are company estimates, not revenue forecasts. The confirmed catalyst is improved potential access; the size and speed of uptake remain uncertain until the policy is final.

Latest Financial Performance

For 2025, revenue increased 14% to $66.5 million and Medicaid revenue rose 37.6% to $29.6 million. Adjusted EBITDA fell 6.4% to $7.5 million, an 11.3% margin, while statutory profit before tax improved to $3.0 million from a $0.9 million loss and net income reached $2.7 million. Arizona reimbursement delays weakened cash conversion and prompted AOTI to stop enrolling new Medicaid patients there from 1 April 2026. Pre-LCD guidance anticipated low-single-digit group revenue growth and a high-single-digit adjusted EBITDA margin.

Operational Performance

AOTI says its commercial footprint spans 26 states and about 86% of the US population, giving it clinical teams, reimbursement expertise and distribution infrastructure if Medicare coverage becomes final. In April, it reported a real-world analysis of 3,126 patients in which 64.8% of wounds healed completely and recurrence was 2.7%. The data are encouraging, but study design, patient selection and comparators must be considered; headline outcomes are not automatically equivalent to a randomised trial.

Balance Sheet, Cash Flow And Funding

Trade and other receivables were $21.8 million at 31 December 2025, reflecting payer timing. AOTI moved from $0.9 million net cash to $6.5 million net debt and drew an $11 million SWK facility. Expansion may require inventory, staff and claims-processing investment before cash is received. Investors should therefore track days sales outstanding, provisions, borrowing headroom and Arizona collections. More billed treatments without matching receipts would not constitute high-quality growth.

Receivables are particularly important because reimbursement businesses can report revenue well before cash arrives. The SWK facility provides liquidity but adds interest and covenant considerations. AOTI will need enough headroom to train providers, support documentation and carry working capital if Medicare volumes increase faster than payer collections.

Recent Announcements And Strategic Developments

The Medicare proposal is the dominant development and remains open to review before finalisation. AOTI has also continued publishing clinical evidence and expanding NEXA. Director share purchases in June offered a limited signal of confidence, but operating delivery matters more. The strategic task is to convert coverage into physician adoption, compliant claims and reliable cash collection.

The proposed LCD also creates an execution window before any effective date. AOTI can use that period to educate clinicians, refine billing processes and plan inventory. Spending too aggressively before final terms would add risk, while underpreparing could allow competitors to capture early adoption once coverage begins.

Industry And Economic Backdrop

Diabetic foot ulcers can become chronic, infected and costly, giving payers an incentive to support therapies that improve healing and reduce recurrence. Coverage still depends on evidence and documentation. AOTI competes with advanced dressings, negative-pressure systems, skin substitutes, hyperbaric oxygen and other interventions, while billing rules and reimbursement decisions can change.

Medicare coverage can influence private payers, but it does not guarantee identical policies. Each insurer may impose its own prior-authorisation, documentation and network rules. The company must therefore build a broad reimbursement capability rather than assume one national decision immediately standardises the market.

Potential Growth Drivers

Final nationwide Medicare coverage would be the largest potential driver. It could add an older and clinically relevant population, improve physician confidence and provide a reference point for Medicaid and commercial insurers. AOTI's installed infrastructure may allow faster uptake than a new entrant.

Other drivers include geographic expansion, greater penetration within existing states, additional evidence for TWO2 and growth of NEXA. The most attractive outcome would be diversified growth across several payer classes rather than dependence on one programme. Higher treatment volumes could also improve operating leverage if reimbursement and collection costs remain controlled.

Upcoming Milestones Or Catalysts

The public-comment period, any revisions to the proposed LCD and publication of final coverage terms are the key regulatory milestones. Investors should examine eligible wound criteria, duration limits, coding, documentation requirements and effective dates, because each can materially affect utilisation.

Operationally, the next financial updates should disclose Arizona receivable progress, Medicare preparation costs, NEXA growth and any change to 2026 guidance. Evidence that cash collections are improving would be as important as new patient starts. Additional real-world or peer-reviewed data could strengthen payer discussions.

Principal Risks And Uncertainties

The proposed LCD may change or take time to implement. Claims can be delayed, disputed or expensive to administer, as Arizona illustrates, while high receivables and net debt reduce flexibility. Clinical outcomes may vary, competing therapies can gain preference and rapid expansion could strain staff and working capital. Management's addressable-market figures describe opportunity, not assured sales.

Concentration in a limited product portfolio adds another risk. Product quality, adverse-event reporting, evidence standards or manufacturing disruption could affect adoption. As the company expands, it must also protect patient information and maintain compliance across different state and federal healthcare requirements.

Investment Perspective

A national Medicare framework would address a major barrier for topical oxygen therapy, and AOTI already has a product, commercial network and supporting evidence. The opportunity has therefore improved materially. The counterweight is a demanding collection profile and higher financial leverage. The company must progress from proposed policy to final coverage, then from coverage to paid treatments. Sustainable cash generation, not the theoretical market size, will decide whether the re-rating lasts.

Outlook

AOTI (LSE: AOTI) shares skyrocketed because proposed Medicare coverage could reshape access to its TWO2 therapy. This is a genuine company-specific catalyst, but it is still an intermediate step. Final policy wording, reimbursement execution, receivable collection and disciplined funding will decide the financial outcome. The stock has entered the spotlight; the next evidence must come from regulation turning into profitable, cash-backed adoption.